Vivos Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RDGL research report →
About the company
Vivos Inc. is a medical technology company focused on radiation oncology, specializing in the development of internal radiation therapy devices for managing tumors that cannot be surgically removed. Their offerings include RadioGel, an injectable particle-gel that utilizes yttrium-90 for targeted radiation treatment of cancerous growths in both humans and animals.
- CEO
- Michael K. Korenko
- IPO
- 1998
- Employees
- 1
- HQ
- Kennewick, WA, US
Price Chart
- Market Cap
- $28.27M
- P/E
- -7.63
- P/S
- 363.84
- P/B
- 9.81
- EV/EBITDA
- -9.11
- Div Yield
- 0.00%
- Gross Margin
- -275.58%
- Op Margin
- -3664.15%
- Net Margin
- -4396.28%
- ROE
- -148.20%
- ROIC
- -101.43%
- Revenue
- $68.38K · 144.25%
- Net Income
- $-3,066,017 · -5.36%
- EPS
- $-0.01 · 4.23%
- Op Income
- $-3,165,047
- FCF YoY
- -28.32%
- 52W High
- $0.15
- 52W Low
- $0.04
- 50D MA
- $0.07
- 200D MA
- $0.07
- Beta
- -0.74
- Avg Volume
- 1.45M
Get TickerSpark's AI analysis on RDGL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Korenko Michael K | buy | 150,000 |
| Sep 15, 25 | Weeks Brad Allan | other | 0 |
| Nov 18, 27 | Weeks Brad Allan | other | 500,000 |
| Dec 31, 25 | Korenko Michael K | buy | 200,000 |
| Dec 2, 25 | Korenko Michael K | buy | 100,000 |
| Nov 20, 25 | Korenko Michael K | buy | 100,000 |
| Aug 14, 25 | Korenko Michael K | buy | 100,000 |
| Oct 28, 24 | Korenko Michael K | buy | 50,000 |
| Sep 30, 24 | Korenko Michael K | buy | 50,000 |
| Aug 13, 24 | Korenko Michael K | buy | 50,000 |
Our RDGL coverage
Recent articles, reports, and earnings notes.
No research on RDGL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RDGL report →Similar companies
Peers in the same neighborhood.